Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. BioInvent International AB's pretax income for the
three
months ended in Jun. 2026 was $-13.12 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-53.07 Mil.
BioInvent International AB's pretax margin was -963.31%.
During the past 13 years, BioInvent International AB's highest Pretax Margin was -13.03%. The lowest was -1526.15%. And the median was -185.61%.
During the past 13 years, BioInvent International AB's highest Pretax Margin was -13.03%. The lowest was -1526.15%. And the median was -185.61%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Pre-Tax Income Related Terms
BioInvent International AB Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOVNF vs VRTX, REGN, MRNA: Pre-Tax Income Comparison
For the Biotechnology subindustry, BioInvent International AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (BOVNF) has a Pre-Tax Income of $-53.07 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on BioInvent International AB and its competitors.
Is BioInvent International AB's Pre-Tax Income too high?
BioInvent International AB's current Pre-Tax Income is $-53.07 Mil. Overall, BioInvent International AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Pre-Tax Income compare to VRTX and REGN?
BioInvent International AB's Pre-Tax Income of $-53.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Pre-Tax Income is $-53.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Pre-Tax Income of $-53.07 Mil. The stock's GF Value™ is $1.09, compared to a current price of $3.29 — trading 201.7% above its estimated fair value. The current Pre-Tax Income is $-53.07 Mil. BioInvent International AB's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Pre-Tax Income is $-53.07 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be overvalued.
The current stock price of $3.29 is trading 201.7% above its estimated GF Value™ of $1.09.
Key valuation signals for BOVNF:
Pre-Tax Income: $-53.07 Mil
GF Value™: $1.09 vs. price of $3.29 (201.7% above fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
37GF Score
Get the complete analysis for BOVNF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
